Chronic Obstructive Pulmonary Disease (COPD) - Drug Pipeline Analysis and Market Forecasts to 2016

The COPD Market is Forecast to Show Positive Growth until 2016

Online PR News – 09-February-2010 – – GlobalData estimated the Chronic Obstructive Pulmonary Disease (COPD) market to be worth $7.2 billion in 2009 and projects it to grow at a compound annual growth rate (CAGR) of 7.4% to reach $11.9 billion in 2016. The development of novel once-daily inhaled therapies is expected to provide new treatment options for COPD patients worldwide, and will play a major role in the expansion of the COPD market in the coming years. A steady increase in the incidence rate, smoking population and in injurious environmental factors in most countries has caused the COPD market to grow significantly.

For further details, please click or add the below link to your browser:

GlobalData has found that the COPD market has high levels of unmet need. Greater unmet needs imply that the market is not well served by the current product options with boundless scope available to new entrants to capture value from underserved segments. Emerging therapies such as long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, long-acting muscarinic antagonists (LAMAs), and LABA/LAMA, will emerge as potentially efficacious entrants over the coming years. There is a need for drugs that can dramatically reduce exacerbation rates, slow or halt the progression of COPD, and improve lung functions and the quality of life in COPD patients. Overall, the market is likely to grow rapidly with the entry of these novel combinational therapies and patient expectations are managed through more efficacious products in near future.

GlobalData has found that Altana Pharma's Roflumilast, Almirall, S.A/Forest Lab's aclidinium bromide, GlaxoSmithKline/Theravance's GW642444, which are in Phase III of clinical development, are the most promising molecules in the COPD treatment pipeline and will drive the COPD market in the near future.
Companies such as GlaxoSmithKline, Novartis AG, Pfizer Inc, AstraZeneca, Forest Laboratories, Merck & Co, Boehringer Ingelheim and Sepracor, Inc have some of the most technologically advanced products in their pipeline portfolios, and are therefore expected to attract investors’ attention.

For further details, please click or add the below link to your browser:

GlobalData has found that the COPD developmental pipeline is strong with over 130 molecules in various phases of clinical development. There are more than 67 first-in-class molecules in different stages of clinical development. These molecules have distinct advantages over the currently marketed players. Trials are being conducted on novel mechanisms and combinational targeted therapies which may improve the symptoms of COPD and prolong the lives of COPD patients. The launch of these innovative products should lead to a decrease in the symptoms of exacerbations, improvements in lung functions and improve patients’ quality of life.
Roflumilast, aclidinium bromide, glycopyrronium bromide, QAB149, GW642444 and other combinational products are the most promising molecules currently in the pipeline. These drugs are part of a new class of therapies that promises to add value to the COPD market in the near future and may strongly compete with the current market players on the basis of better efficacy and safety profiles.

GlobalData, the industry analysis specialist, has released its latest research, “Chronic Obstructive Pulmonary Disease (COPD) - Drug Pipeline Analysis and Market Forecasts to 2016” which provides the key data, information and analysis on the COPD market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with COPD, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the COPD market.

For further details, please click or add the below link to your browser:

Or visit our report store:

Contact Information
Rajesh Gunnam
Progressive House, Maidstone Road, Foots Cray, Sidcup
Kent London, DA14 5HZ